术后甲胎蛋白反应预测肝细胞癌肝切除后肿瘤复发与生存:倾向性评分匹配分析
该回顾性研究纳入2009至2011年复旦大学附属中山医院841例以治愈性肝切除为初始治疗的肝细胞癌患者,检测术前及术后1周血清甲胎蛋白,计算甲胎蛋白反应(AR=lgAFP7/lgAFP0),确定最佳截断值0.8135,将患者分为反应者(≤0.8135,n=452)与非反应者(>0.8135,n=146)。多因素Cox分析显示甲胎蛋白反应独立预测总生存(OS)和无复发生存(RFS)(均P<.001),并在倾向性评分匹配人群及另一独立队列中验证。
要点
- 术后1周甲胎蛋白反应(AR)最佳截断值为0.8135。
- AR≤0.8135的反应者OS和RFS优于非反应者(均P<.001)。
- 在单发伴微血管侵犯或多发肿瘤的高复发风险患者中,反应者生存更优(P<.05)。
核心结论
- 术后甲胎蛋白反应是评估肝细胞癌手术切除肿瘤学效果的可靠且简单的预测标志物,独立于肿瘤特征。
研究设计与样本
- 回顾性分析2009至2011年复旦大学附属中山医院841例以治愈性肝切除为初始治疗的肝细胞癌患者。
- 检测术前(AFP0)和术后1周(AFP7)血清甲胎蛋白,按公式AR=lgAFP7/lgAFP0计算甲胎蛋白反应。
- 结果在倾向性评分匹配人群及同一机构另一独立队列中验证。
主要发现
- 甲胎蛋白反应最佳截断值为0.8135,据此将探索队列分为反应者(≤0.8135,n=452)和非反应者(>0.8135,n=146)。
- 多因素Cox分析显示甲胎蛋白反应独立预测OS和RFS(均P<.001)。
- 在单发伴微血管侵犯或多发肿瘤的高复发风险患者中,反应者生存优于非反应者(P<.05)。
关键数值与推荐
- 甲胎蛋白反应最佳截断值:0.8135。
- 反应者定义:AR≤0.8135;非反应者定义:AR>0.8135。
- 多因素Cox分析中甲胎蛋白反应预测OS和RFS的P值均<.001。
- 高复发风险亚组中反应者与非反应者生存比较P<.05。
临床怎么用
- 对术前甲胎蛋白阳性的肝细胞癌患者,术后1周检测甲胎蛋白并计算AR可辅助评估手术切除的肿瘤学效果。
- AR≤0.8135提示反应者,其OS和RFS更优,尤其在高复发风险患者中可考虑更密切随访或辅助治疗决策参考。
局限性
- 回顾性研究设计。
- 研究人群来自单一机构(复旦大学附属中山医院)。
- 仅纳入术前甲胎蛋白阳性的肝细胞癌患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To investigate the prognostic values of the change of α-fetoprotein within 1 week after resection of hepatocellular carcinoma. METHODS: We retrospectively analyzed patients with hepatocellular carcinoma who underwent curative hepatectomy as primary therapy at Zhongshan Hospital, Fudan University (Shanghai, China) from 2009 to 2011. We measured serum α-fetoprotein before (α-fetoprotein0) and 1 week after (α-fetoprotein7) hepatectomy, calculated change of α-fetoprotein, namely the α-fetoprotein response by the formula: AR = lgAFP7/lgAFP0 (lg = log10), analyzed the relationship between patient survival and α-fetoprotein response, and explored the potential clinical implications of the α-fetoprotein response. The results were validated in an independent cohort of patients from the same institute. RESULTS: A total of 841 eligible patients were analyzed. We determined that the optimal cutoff value of the α-fetoprotein response was 0.8135 and subsequently classified patients from the exploration cohort into the α-fetoprotein responder (α-fetoprotein response ≤ 0.8135; n = 452) and α-fetoprotein nonresponder (α-fetoprotein response > 0.8135; n = 146). Multivariate Cox analysis showed that the α-fetoprotein response independently predicted overall survival (OS) and recurrence-free survival (RFS) time after resection (both P < .001). In patients with a higher risk of tumor recurrence (either single tumor with microvascular invasion or multiple tumors), α-fetoprotein responders were associated with better survival than the nonresponders (P < .05). The results were validated by propensity score matched population and another independent cohort. CONCLUSION: The α-fetoprotein response is a reliable and simple predictive marker for evaluating the oncological effect of surgical resection for hepatocellular carcinoma with positive α-fetoprotein before resection, independent of tumor features.
引用
- Li XL, Zhu XD, Cai H, et al. Postoperative α-fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis. Surgery. 2019. PMID: 30846192. doi:10.1016/j.surg.2019.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。